UNSPSC 51372117: Dihydrocodeine bitartrate

This classification denotes an opioid receptor agonist and opioid with the molecular formula C18H23NO3.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8LXS95BSA9, chemically known as 7, 8-dihydrocodeine but more generally known as dihydrocodeine bitartrate, which bears US NIH Compound Identifier 3063. European Medicines Agency schedules Dihydrocodeine bitartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01704MIG.

UNSPSC 51372117 Dihydrocodeine bitartrate is a Commodity code tracking a specific controlled pharmaceutical. State and local procurement activity under this code focuses on acquiring pharmaceutical products—including opioids, naloxone, and generic multi-source medications—to support public health, emergency response, and community health programs. Recent solicitations show that state and local governments are procuring controlled substances and allied drug products through both direct purchases and cooperative purchasing frameworks, often requiring vendors to navigate FDA compliance, Drug Supply Chain Security Act (DSCSA) certification, and current Good Manufacturing Practices (cGMP) standards. Issuing bodies include county health departments, state health and human services agencies, and multi-state cooperative purchasing alliances coordinating acquisitions across member jurisdictions. Vendors must typically maintain federal authorization to distribute controlled substances, comply with E-Verify and drug-free workplace requirements, and demonstrate financial stability through insurance coverage mandates including commercial general liability and professional liability policies.

The code sees active procurement across Florida and the upper Midwest, with multi-state cooperative purchasing vehicles broadening geographic reach. Seminole County, Florida recently issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to its Community Health Building, with a response deadline of July 26, 2023, under a two-year term with one-year renewal option. The Texas Health and Human Services Commission released RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a direct-to-manufacturer prescription program serving state employees and self-insured health plans. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed through authorized wholesalers across member states including Oregon, with responses due March 26, 2026, and contract effectiveness July 1, 2026. Cooperative purchasing vehicles represent a significant channel for manufacturers seeking to reach multiple state and local jurisdictions simultaneously.